budoprutug

Phase 2Small molecule

TTenet Medicines

budoprutug is one of 112 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Immune ThrombocytopeniaActive, not recruiting

Membranous NephropathyActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Immune ThrombocytopeniaPhase 1/Phase 2

Active, not recruiting

Membranous NephropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Rituxan

Roche

Phase 3

9 3

Medrol

Pfizer

Phase 3

5 4

Olumiant

Eli Lilly

Phase 3

4 5

Rinvoq

AbbVie

Phase 3

3 6

Ocrevus

Roche

Phase 3

2 7

Gazyva

Roche

Phase 3

2 8

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 9

Rayos

RRoxane Laboratories

Phase 3

6 10

Depo-Provera

Eli Lilly

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT07011043

Q4 2027

Phase 2Recruiting

Membranous Nephropathy

NCT07096843

Q3 2028

Phase 1/2Recruiting

Immune Thrombocytopenia

NCT07043946

Clinical

Trials by Indication[1]

Membranous Nephropathy1 trial

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Recruiting·CClimb Bio, Inc.·Phase 2·NCT07096843·45 enrolled

Immune Thrombocytopenia1 trial

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Recruiting·CClimb Bio, Inc.·Phase 1/2·NCT07043946·24 enrolled

Intravenous1 trial

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

Active, not recruiting·CClimb Bio, Inc.·Phase 1·NCT07090655·38 enrolled

Phase 11 trial

Phase 1b/2a in SLE With Budoputug

Withdrawn·TTenet Medicines·Phase 1/2·NCT06570434

Systemic Lupus Erythematosus1 trial

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Recruiting·CClimb Bio, Inc.·Phase 1·NCT07011043·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for budoprutug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — budoprutug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for budoprutug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tenet Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTenet Medicines

budoprutug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q3 2028

Trials by Indication[1]

Membranous Nephropathy1 trial

Immune Thrombocytopenia1 trial

Intravenous1 trial

Phase 11 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News